Our mission is to develop therapies that empower the immune system to cure neurodegeneration.

We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, which is often associated with debilitating conditions such as dementia and Alzheimer’s disease.

Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. We are developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain.

Our Discovery Platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology, enabling us to advance a broad portfolio of product candidates that we believe have an improved probability of technical success over shorter development timelines. Our current drug discovery and development portfolio can be found here.

Press Releases
Alector Announces First Frontotemporal Dementia Patient Dosed in Phase 1b Study of AL001
Alector Initiates Phase 1 Trial of AL003 for the Treatment of Patients with Alzheimer’s Disease
Alector Reports Recent Business Highlights and Fourth Quarter and Full Year 2018 Financial Results